JP2025503970A - 化合物及び使用方法 - Google Patents
化合物及び使用方法 Download PDFInfo
- Publication number
- JP2025503970A JP2025503970A JP2024544445A JP2024544445A JP2025503970A JP 2025503970 A JP2025503970 A JP 2025503970A JP 2024544445 A JP2024544445 A JP 2024544445A JP 2024544445 A JP2024544445 A JP 2024544445A JP 2025503970 A JP2025503970 A JP 2025503970A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- pharma
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303451P | 2022-01-26 | 2022-01-26 | |
| US63/303,451 | 2022-01-26 | ||
| PCT/US2023/011661 WO2023146991A1 (en) | 2022-01-26 | 2023-01-26 | Compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503970A true JP2025503970A (ja) | 2025-02-06 |
| JP2025503970A5 JP2025503970A5 (https=) | 2026-02-16 |
Family
ID=85328903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544445A Pending JP2025503970A (ja) | 2022-01-26 | 2023-01-26 | 化合物及び使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250282749A1 (https=) |
| EP (1) | EP4469445A1 (https=) |
| JP (1) | JP2025503970A (https=) |
| WO (1) | WO2023146991A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| CN119731162A (zh) * | 2022-08-19 | 2025-03-28 | 北京望实智慧科技有限公司 | Prmt5抑制剂 |
| CN120476118A (zh) * | 2023-01-17 | 2025-08-12 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| CN120457129A (zh) * | 2023-01-31 | 2025-08-08 | 四川科伦博泰生物医药股份有限公司 | 草酸二酰胺化合物、包含其的药物组合物及其制备方法和用途 |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| US20250312344A1 (en) * | 2024-04-08 | 2025-10-09 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| WO2025217297A1 (en) | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| CA2899363A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
| WO2022026892A1 (en) * | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
-
2023
- 2023-01-26 WO PCT/US2023/011661 patent/WO2023146991A1/en not_active Ceased
- 2023-01-26 EP EP23706925.7A patent/EP4469445A1/en active Pending
- 2023-01-26 JP JP2024544445A patent/JP2025503970A/ja active Pending
- 2023-01-26 US US18/833,468 patent/US20250282749A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023146991A1 (en) | 2023-08-03 |
| US20250282749A1 (en) | 2025-09-11 |
| EP4469445A1 (en) | 2024-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12264154B2 (en) | Compounds and methods of use | |
| US12403137B2 (en) | Compounds and methods of use | |
| EP4291559A1 (en) | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer | |
| JP2025503970A (ja) | 化合物及び使用方法 | |
| JP2025503969A (ja) | 化合物及び使用方法 | |
| JP2024511996A (ja) | 抗がん剤としてのプリン誘導体 | |
| JP2025503971A (ja) | 化合物及び使用方法 | |
| US11986471B2 (en) | Compounds and methods of use | |
| JP2025504916A (ja) | 化合物及び使用方法 | |
| US20230192679A1 (en) | Crystalline forms, pharmaceutical compositions and methods of use thereof | |
| CN118715207A (zh) | 化合物和使用方法 | |
| WO2026090589A1 (en) | Heterocyclic hbs1l degraders | |
| WO2026073277A1 (en) | Substituted piperidine-diones inactivating hbs1l | |
| EA052682B1 (ru) | Производные пиперидин-1-ил-n-пиридин-3-ил-2-оксоацетамида, пригодные для лечения раковых заболеваний с дефицитом мтар и/или с накоплением мта |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260205 |